Updated September 26, 2026. This educational article replaces earlier claims that overstated the benefits and safety of sermorelin.
Sermorelin is a synthetic fragment of growth hormone–releasing hormone. It stimulates responsive cells in the pituitary gland to release growth hormone; it does not work by making the hypothalamus release GHRH. A change in a hormone measurement does not, by itself, establish a meaningful health benefit.
Growth hormone deficiency needs a diagnosis
For example, persistent tiredness, poor sleep, or changes in body composition can have many causes. They do not establish growth hormone deficiency. Evaluation considers medical history, pituitary disease, other hormone findings, and appropriate testing. An endocrinologist may recommend a stimulation test rather than relying on a single growth hormone result. See the Endocrine Society guidance on adult growth hormone deficiency.
What approval and research do—and do not—show
Sermorelin historically held approval as Geref for selected pediatric uses. That history does not establish approval for adult anti-aging, weight loss, insomnia, or athletic recovery. FDA’s 2024 review states that the agency has not approved growth hormone secretagogues to treat growth hormone deficiency in adults. It also distinguishes stimulation of a functioning pituitary from replacement with growth hormone. Read the FDA review.
The earlier version of this article claimed that sermorelin lowers blood pressure, improves cholesterol and cognition, prevents fractures, and reverses aging. We should not have presented those claims as established benefits. Neither a small hormone-response study nor a patient’s testimonial establishes those outcomes. We also removed an unsupported recommendation to inject glycine for fatigue, insomnia, or prostate symptoms.
Safety and treatment decisions
Do not assume that stimulating your own hormone production makes a treatment risk-free or safer than an approved alternative. Discuss the evidence for your specific diagnosis, the exact preparation, potential adverse effects, medication interactions, and monitoring with your clinician. A compounded preparation is not an FDA-approved product.
There is no reliable universal timetable for improvement or basis for promising that benefits outweigh risks for every patient. In addition, new symptoms during treatment warrant review by the prescriber rather than simply increasing treatment.
Questions to bring to a consultation
- What diagnosis explains my symptoms, and what testing is appropriate?
- Does the proposed product have approval for this use, or is it a compounded or investigational product?
- What patient outcomes support it, rather than changes in a laboratory marker alone?
- Finally, what alternatives, follow-up checks, and stopping criteria should we discuss?
Explore our guide to peptide therapy or schedule an evaluation to discuss your symptoms and options. An appointment does not guarantee a prescription for a particular drug.
